• Sort by

  • Industry

Toggle intro on/off

Coles Group (COL) - 1H26 result analysis

Moving past the strikes

03 March 2026

Coles Group reported 2.5% sales growth and 10.2% EBIT growth in 1H26. The key driver of earnings was higher gross profit margins, which should persist in 2H26e, but then fade in future years. Cost savings and productivity benefits from its supply chain investment are also boosting profit margins. Coles sales trends have slowed highlighting the Woolworths DC strike benefit was transitory. However, its growth still outstripped Woolworths on a two-year basis. Coles has de-rated over the past month and its sales momentum is likely to converge with Woolworths over the next 3-6 months.

Coles Group Ltd (COL) - 1Q26 sales result

It’s tough at the top

03 November 2025

Coles Group reported 1Q26 sales growth of 3.9% and an impressive 4.6% comparable sales growth in its Supermarkets. While the result is strong, the momentum is likely to slow as its larger rival Woolworths starts to improve its execution. Coles also faces a 2Q26e hurdle from DC strike benefits in 2Q25 and a diminishing contribution from new stores. We expect Liquor EBIT to decline again in FY26e.

Sigma Healthcare Ltd (SIG) - 2025 AGM trading update

Over-sized sales growth

27 October 2025

Sigma Warehouse reported its 1Q26 sales at its AGM. Chemist Warehouse like-for-like sales were up 14.7% for the quarter, an acceleration on FY25 trends. The company highlighted elevated sales of weight-loss drugs like Ozempic as a big contributor. We estimate the contribution is anywhere from 3%-5% of the LFL growth. We expect LFL sales to settle back at 11% in 2Q26e and 9.0% in 2H26e.

Sigma Healthcare (SIG) - FY25 result analysis

Injecting leverage into sales

10 September 2025

Sigma reported FY25 network sales growth for Chemist Warehouse of 14% and EBIT at $903 million, up 47%. The company reported a continuation of double-digit like-for-like sales growth with a lift in profit margins for the underlying Chemist Warehouse business. We forecast EBIT growth of 22% in FY26e ahead of revenue growth of 15%. Margins will be helped by penetration of Wagner private label, operating leverage from strong comp sales and the increasing synergies over the next four years.

Coles (COL) - FY25 result analysis

A banner year ahead

05 September 2025

Coles reported FY25 EBIT up 7.5% on a 52-week basis. Growth was stronger in Supermarkets, partly offset declines in Liquor and higher overheads. Coles has had a strong start to FY26e sales in Supermarkets, which we largely attribute to market share gains. The combination of better sales, one-off costs from last year rolling off and supply chain savings should support group EBIT growth of 12.5% in FY26e. We expect growth to then step down to 5%-7% in FY27e and beyond.

Price Watch Issue 7 - The price of substitutes

Assessing relative price movements

22 December 2023

Retail prices have risen substantially over the past three years in Australia, and surprisingly there has been little damage to volumes. In Issue 7 of Price Watch, we assess the relative price movements in retail. Retail price inflation has generally only tracked broader inflation and therefore its relative affordability remains good. Moreover, our analysis across many large retailers reveals they have been meticulous in ensuring price relativities between brands and private labels have been held. Even with sensible measures on price, retailers should brace for a consumer that will increasingly substitute to different pack sizes, brands or even delay their purchase. These behaviours tend to build over time in both food and non-food retail categories.

Search result for "" — 625 articles found

Not already a member?
Join now to get all the latest reports in full and stay informed.

Get started